Sudden Sensorineural Hearing Loss Clinical Trial
Official title:
Phase I Clinical Study on the Safety, Tolerance, Efficacy and Pharmacokinetics of Repeated Intratympanic HY01 in Patients With Sudden Sensorineural Hearing Loss
Phase I clinical study on the safety, tolerance, efficacy and pharmacokinetics of repeated intratympanic HY01 in patients with sudden sensorineural hearing loss. In this study, low-dose group and high-dose group were designed, 6 cases in each group.
The incidence rate of sudden deafness is increasing year by year, which can cause severe hearing loss. Intratympanic HY01 can increase the local drug concentration in the ear, which is equal to or better than that in the treatment of sudden sensorineural hearing loss, and reduce the systemic drug concentration at the same time. It has obvious clinical value for the treatment of hormone forbidden population. HY01 is one of glucocorticoid drugs. In this study, we designed low-dose group and high-dose group of HY01, and enrolled 6 patients with sudden sensorineural hearing loss for salvage therapy in each group. HY01 will be administrated on D1, D4 and D7 . The trial will be ended 30 days after the first administration. After determining the safety of low-dose, the patients in the high-dose group will be enrolled. The safety observation indexes included systemic Routine Indexes and otology indexes, and the efficacy and pharmacokinetics were observed at the same time. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04120116 -
FX-322 in Adults With Stable Sensorineural Hearing Loss
|
Phase 2 | |
| Recruiting |
NCT05403229 -
The Role of Migraine Prophylaxis Agent Topiramate in Treating Patients With Sudden Sensorineural Hearing Loss
|
Phase 2 | |
| Not yet recruiting |
NCT05608161 -
Speech Perception Impairment Follow Complete Recovery of Sudden Sensorineural Hearing Loss
|
||
| Recruiting |
NCT06278129 -
Evaluation of the Diagnostic and Prognostic Efficacy of MRI in Acute Sensorineural Hearing Loss and Ménière's Disease
|
||
| Recruiting |
NCT06249919 -
A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patients
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04826237 -
Oral Statins and Protection From Hearing Loss
|
Phase 4 | |
| Recruiting |
NCT05849519 -
Small Sample，Unicentric，Randomized, Controlled Clinical Study of Coenzyme I for Injection in the Treatment of Sudden Sensorineural Hearing Loss
|
Early Phase 1 | |
| Not yet recruiting |
NCT04224909 -
Video HIT in Sudden Sensorineural Hearing Loss
|
||
| Not yet recruiting |
NCT06365775 -
Multi-omics Characteristics and Prognosis of Idiopathic Sudden Sensorineural Hearing Loss
|
||
| Not yet recruiting |
NCT06355102 -
The Development of Tinnitus in Patients With SSNHL: Insights From fMRI and Metabolomics
|